Kevin Moore, MD
Dermatology · Boston, MANPI 1164927042
Payments from drug & device makers
Across 87 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$438
- E.r. Squibb & Sons, L.L.C.$228
- Sanofi$144
- Johnson & Johnson$143
- Incyte Corporation$133
- LEO Pharma Inc.$125
- plus $486 from 12 others
What the payments were for
- Food & beverage$1,698100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $438 |
| E.r. Squibb & Sons, L.L.C. | 9 | $228 |
| Sanofi | 6 | $144 |
| Johnson & Johnson | 6 | $143 |
| Incyte Corporation | 6 | $133 |
| LEO Pharma Inc. | 5 | $125 |
| Regeneron Healthcare Solutions, Inc. | 4 | $99 |
| Novartis | 3 | $66 |
| Sun Pharmaceutical Industries Inc. | 2 | $47 |
| Arcutis Biotherapeutics, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $43 |
| UCB, Inc. | 2 | $36 |
| Organon | 1 | $31 |
| GSK | 1 | $31 |
| Verrica Pharmaceuticals Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $24 |
| Biofrontera Inc. | 1 | $21 |
| Amgen | 1 | $18 |
How this compares
$1,698 in reported general payments places this provider in the 55th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $63,334 |
| Clobetasol Propionate | 53 | $3,032 |
| Mupirocin | 236 | $1,616 |
| Cephalexin | 213 | $902 |
| Ketoconazole | 54 | $865 |
| Gentamicin Sulfate | 16 | $800 |
| Doxycycline Hyclate | 105 | $591 |
| Triamcinolone Acetonide | 27 | $499 |
| Minoxidil | 16 | $351 |
| Mometasone Furoate | 14 | $253 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $119 |
| Hydrocortisone | 19 | $110 |
| Clindamycin Hcl | 16 | $44 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Boston
- Alexandra KimballBoston$3.7M
- Gideon SmithBoston$2.6M
- Tarannum JaleelBoston$1.3M
- Maria Beatrice AloraBoston$1.3M
- Martina PorterBoston$1.1M
- Arash MostaghimiBoston$1M
- Emmy GraberBoston$882K
- Ruth Ann VleugelsBoston$786K
- Maryanne SennaBoston$783K
- Gabriela CobosBoston$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.